<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811263</url>
  </required_header>
  <id_info>
    <org_study_id>P0511976</org_study_id>
    <nct_id>NCT02811263</nct_id>
  </id_info>
  <brief_title>High-dose Erythropoietin for Asphyxia and Encephalopathy</brief_title>
  <acronym>HEAL</acronym>
  <official_title>High-dose Erythropoietin for Asphyxia and Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mednax Center for Research, Education, Quality and Safety</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoxic-ischemic encephalopathy (HIE) occurs when a baby gets reduced blood flow and oxygen
      to the brain near the time of birth. This results in death or neurologic disabilities
      including cerebral palsy and cognitive impairment in up to half of affected infants. This
      clinical trial will determine if the drug erythropoietin (Epo) added to hypothermia (usual
      therapy) will improve outcomes for infants suffering from HIE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neonatal hypoxic-ischemic encephalopathy (HIE) refers to brain injury resulting from reduced
      blood and oxygen flow to a baby's brain near the time of birth. HIE affects up to 12,000
      newborns each year in the U.S. Half of affected infants have a bad outcome including death,
      cerebral palsy and cognitive impairment despite receiving hypothermia, the only available
      treatment. Erythropoietin (Epo) is a cytokine with remarkable neuroprotective and
      neuroregenerative effects demonstrated in animal models of neonatal brain injury. In a phase
      I trial of Epo + hypothermia, the investigators found that Epo 1000 U/Kg/dose best reproduced
      the pharmacokinetics of neuroprotective dosing in animal models. Long term outcomes were
      better than expected based on entry criteria and MRI findings. A phase II trial compared 50
      cooled infants randomized to receive Epo or placebo. Infants treated with hypothermia + Epo
      had less brain injury on early MRI, and better 12-month motor development. The investigators
      hypothesize that Epo given to cooled infants with moderate/severe HIE will reduce the
      combined primary outcome of death or neurodevelopmental impairment from 49 to 33%. This is a
      randomized, double-blind, placebo-controlled trial of Epo therapy in 500 infants with HIE
      undergoing hypothermia. Specific aims are 1) To determine if 5 doses of Epo 1000 U/kg IV
      reduces the rate of death, motor or cognitive deficits at 2 years; 2) To assess safety of Epo
      by evaluating clinical toxicity; and 3) To determine whether Epo decreases the severity of
      neonatal brain injury as evidenced by early MRI and circulating biomarkers of brain injury.
      The investigators anticipate that Epo will confer improved 2-year neurodevelopmental outcome,
      will be safe, and will decrease brain injury severity as determined by early biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death or moderate/severe neurodevelopmental impairment</measure>
    <time_frame>Prior to final outcome assessment at 22-26 months of age</time_frame>
    <description>Neurodevelopmental impairment defined as any of the following: a) Gross Motor Function Scale (GMFCS) level ≥ 2, or b) GMFCS = 1 and cerebral palsy (CP) (any type), or c) GMFCS = 0 or 0.5 and quadriparetic CP, or d) Bayley III Cognitive Score &lt; 85</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence and type of cerebral palsy (CP) determined using a standardized neurologic examination</measure>
    <time_frame>22-26 months</time_frame>
    <description>Neurologic diagnoses: no CP, diparetic CP, hemiparetic CP, quadriparetic CP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of gross motor function determined using the GMFCS</measure>
    <time_frame>22-26 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bayley III cognitive and language scores</measure>
    <time_frame>22-26 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of epilepsy</measure>
    <time_frame>Prior to 22-26 months</time_frame>
    <description>≥ 2 afebrile, unprovoked seizures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral abnormalities determined by the externalizing score of the Child Behavior Checklist</measure>
    <time_frame>22-26 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Rates of Epo-related adverse events</measure>
    <time_frame>Through hospital discharge</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rates of Epo-related adverse events</measure>
    <time_frame>Through 22-26 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serial circulating biomarkers of inflammation/brain injury</measure>
    <time_frame>During first week of life</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>MR evidence of brain injury</measure>
    <time_frame>During first week of life</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Neonatal Encephalopathy</condition>
  <condition>Birth Asphyxia</condition>
  <arm_group>
    <arm_group_label>Erythropoietin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Erythropoietin 1000 U/kg IV, at about 1, 2, 3, 4 and 7 days of age (i.e., 5 doses)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline IV (equal volume), at about 1, 2, 3, 4 and 7 days of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline placebo</intervention_name>
    <description>Equal volume of normal saline to be used as placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>NS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>Epogen drawn from commercially available single dose 4000U/mL vials</description>
    <arm_group_label>Erythropoietin</arm_group_label>
    <other_name>Epogen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 36 weeks of gestational age

          -  Receiving active or passive whole body cooling/hypothermia since &lt; 6 hours of age

          -  Perinatal depression based on at least one of the following:

               1. Apgar score &lt; 5 at 10 minutes, or

               2. Need for resuscitation at 10 minutes (i.e., endotracheal or mask ventilation, or
                  chest compressions), or

               3. pH &lt; 7.00 in cord, arterial, or venous blood &lt; 60 minutes of age

               4. Base deficit ≥ 15 mmol/L in cord, arterial, or venous blood &lt; 60 minutes of age

          -  Moderate to severe encephalopathy (based on modified Sarnat exam) present between 1-6
             hours after birth

        Exclusion Criteria:

          -  Study drug unlikely to be administered within 26 hours of birth

          -  Infant has living twin (or higher order multiple) who is also being cooled

          -  Birth weight &lt; 1800 g (e.g., intrauterine growth restriction)

          -  Genetic or congenital condition that affects neurodevelopment or requires multiple
             surgeries (e.g., congenital viral infection, hydrops, complex congenital heart
             disease, severe dysmorphic features, etc.)

          -  Head circumference &lt; 30 cm

          -  Redirection of care is being considered due to moribund condition

          -  Patient anticipated to be unavailable for evaluation at age 2

          -  Polycythemia (hematocrit &gt; 65%)

          -  Parents with diminished capacity and autonomy

          -  Infant is participating in another interventional study (note: does not include
             observational studies)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvonne Wu, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandra Juul, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yvonne Wu, MD MPH</last_name>
    <email>wuy@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra Juul, MD PHD</last_name>
    <email>sjuul@uw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tai-Wei Wu, MD</last_name>
      <email>twu@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Tai-Wei Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krisa Van Meurs, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Ball, RN</last_name>
      <phone>(650) 725-8342</phone>
      <email>mbball@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Krisa Van Meurs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Gonzalez, MD</last_name>
      <email>Fernando.Gonzalez@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Fernando Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yvonne Wu, MD MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taeun Chang, MD</last_name>
      <phone>202-259-0170</phone>
      <email>tchang@cnmc.org</email>
    </contact>
    <investigator>
      <last_name>Taeun Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>An Massaro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Mietzsch, MD</last_name>
      <email>umietzsc@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Ulrike Mietzsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mandy Harris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota: Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Bendel-Stenzel, MD</last_name>
      <email>Ellen.Bendel-Stenzel@childrensmn.org</email>
    </contact>
    <investigator>
      <last_name>Ellen Bendel-Stenzel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota: St. Paul</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Lampland, MD</last_name>
      <email>lampl002@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Andrea Lampland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Mathur, MD</last_name>
      <phone>314-454-4031</phone>
      <email>mathur_a@kids.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Amit Mathur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert McKinstry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Poindexter, MD MS</last_name>
      <email>Brenda.Poindexter@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Brenda Poindexter, MD MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Poindexter, MD MS</last_name>
      <email>Brenda.Poindexter@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Brenda Poindexter, MD MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Maitre, MD</last_name>
      <email>nathalie.Maitre@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Nathalie Maitre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Flibotte, MD</last_name>
      <email>flibottej@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>John Flibotte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toby Yaoniwtz, MD</last_name>
      <email>yanotd@mail.magee.edu</email>
    </contact>
    <investigator>
      <last_name>Toby Yanowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashok Panigrahy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magee Women's Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toby Yanowitz, MD</last_name>
      <email>yanotd@mail.magee.edu</email>
    </contact>
    <investigator>
      <last_name>Toby Yanowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashok Panigrahy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hendrik Weitkamp, MD</last_name>
      <email>hendrik.weitkamp@Vanderbilt.Edu</email>
    </contact>
    <investigator>
      <last_name>Hendrik Weitkamp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lina Chalak, MD</last_name>
      <email>Lina.Chalak@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Lina Chalak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Hospital</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Riley, MD</last_name>
      <email>David.Riley@cookchildrens.org</email>
    </contact>
    <investigator>
      <last_name>David Riley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaashif Ahmad, MD</last_name>
      <email>kaashif_ahmad@pediatrix.com</email>
    </contact>
    <investigator>
      <last_name>Kaashif Ahmad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Children's Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaashif Ahmad, MD</last_name>
      <email>kaashif_ahmad@pediatrix.com</email>
    </contact>
    <investigator>
      <last_name>Kaashif Ahmad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Baserga, MD MSCI</last_name>
      <email>mariana.baserga@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Mariana Baserga, MD MSCI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Baserga, MD MSCI</last_name>
      <email>mariana.baserga@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Mariana Baserga, MD MSCI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis Mayock, MD</last_name>
      <phone>206-543-5257</phone>
      <email>mayock@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Dennis Mayock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Juul, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis Mayock, MD</last_name>
      <phone>206-543-5257</phone>
      <email>mayock@u.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Dennis Mayock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Juul, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wu YW, Mathur AM, Chang T, McKinstry RC, Mulkey SB, Mayock DE, Van Meurs KP, Rogers EE, Gonzalez FF, Comstock BA, Juul SE, Msall ME, Bonifacio SL, Glass HC, Massaro AN, Dong L, Tan KW, Heagerty PJ, Ballard RA. High-Dose Erythropoietin and Hypothermia for Hypoxic-Ischemic Encephalopathy: A Phase II Trial. Pediatrics. 2016 Jun;137(6). pii: e20160191. doi: 10.1542/peds.2016-0191. Epub 2016 May 2.</citation>
    <PMID>27244862</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu YW, Bauer LA, Ballard RA, Ferriero DM, Glidden DV, Mayock DE, Chang T, Durand DJ, Song D, Bonifacio SL, Gonzalez FF, Glass HC, Juul SE. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics. 2012 Oct;130(4):683-91. doi: 10.1542/peds.2012-0498. Epub 2012 Sep 24.</citation>
    <PMID>23008465</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Yvonne Wu</investigator_full_name>
    <investigator_title>Professor of Neurology and Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Asphyxia</mesh_term>
    <mesh_term>Asphyxia Neonatorum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

